{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.78","value":"2482"},{"groupId":"OG001","spread":"33.19","value":"3074"},{"groupId":"OG002","spread":"31.12","value":"2784"},{"groupId":"OG003","spread":"49.75","value":"2569"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.15","value":"203.7"},{"groupId":"OG001","spread":"33.67","value":"242.6"},{"groupId":"OG002","spread":"30.91","value":"222.3"},{"groupId":"OG003","spread":"41.19","value":"198.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: N-desmethyl selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.06","value":"4041"},{"groupId":"OG001","spread":"49.45","value":"3841"},{"groupId":"OG002","spread":"50.90","value":"3943"},{"groupId":"OG003","spread":"27.13","value":"3249"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.34","value":"247.5"},{"groupId":"OG001","spread":"33.49","value":"247.0"},{"groupId":"OG002","spread":"33.25","value":"247.2"},{"groupId":"OG003","spread":"22.82","value":"238.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: N-desmethyl selumetinib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"To further evaluate the PK of the granule formulation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Global Cohort 1 (\\>=4 to \\<7 years)","id":"OG000","title":"Global Cohort 1"},{"description":"Global Cohort 2 (\\>=1 to \\<4 years)","id":"OG001","title":"Global Cohort 2"},{"description":"Global Cohorts (\\>=1 to \\<7 years)","id":"OG002","title":"Total in Global"},{"description":"Japan Cohort (\\>=1 to \\<7 years)","id":"OG003","title":"Japan Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 3, 4, 6, 8, 10-12, and 18-24 hours post-dose after selumetinib single dose on the first day of treatment (Cycle 1 Day 1). Pre-dose and 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)","title":"Selumetinib and N-desmethyl Selumetinib BSA Normalised AUC0-12 After Single and Multiple Dose Administration","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"(h*ng/mL)/m2"}